Processing

Please wait...

Settings

Settings

1. WO2013106577 - ENHANCEMENT OF TRANSPORT OF THERAPEUTIC MOLECULES ACROSS THE BLOOD BRAIN BARRIER

Publication Number WO/2013/106577
Publication Date 18.07.2013
International Application No. PCT/US2013/021041
International Filing Date 10.01.2013
IPC
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46
Hybrid immunoglobulins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25
Drugs for disorders of the nervous system
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
48
the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C07K 16/28 (2006.01)
C07K 16/46 (2006.01)
A61P 25/00 (2006.01)
A61K 47/48 (2006.01)
CPC
A61K 2039/505
A61K 39/00
A61K 47/50
C07K 14/415
C07K 14/4702
C07K 16/28
Applicants
  • BIOGEN IDEC MA INC. [US/US]; 14 Cambridge Center Cambridge, MA 02142, US
Inventors
  • FARRINGTON, Graham, K.; US
  • SISK, William; US
Agents
  • BRENNAN, Jack; Fish & Richardson P.C. P.O. Box 1022 Minneapolis, Minnesota 55440-1022, US
Priority Data
61/585,03910.01.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ENHANCEMENT OF TRANSPORT OF THERAPEUTIC MOLECULES ACROSS THE BLOOD BRAIN BARRIER
(FR) AMÉLIORATION DU TRANSPORT DE MOLÉCULES THÉRAPEUTIQUES À TRAVERS LA BARRIÈRE HÉMATO-ENCÉPHALIQUE
Abstract
(EN)
The invention is based, at least in part, on the finding that a dimeric version of a BBB-transmigrating antibody (e.g., theTMEM30A (CDC-50A) binding antibody, FC5) was found to greatly enhance transport across the BBB as compared to monovalent FC5 VHH. The invention provides, inter alia, molecules that increase transport of pharmacologically active agents across the blood brain barrier, methods for increasing transport across the blood brain barrier, and methods of treatment of disorders or diseases having a neurological component.
(FR)
L'invention se base, au moins en partie, sur la découverte selon laquelle une version dimère d'un anticorps capable de transmigrer à travers la BHE (par exemple, l'anticorps se liant à TMEM30A (CDC-50A), FC5) s'est avérée améliorer grandement le transport à travers la BHE par rapport à FC5 VHH monovalent. L'invention concerne, entre autres, des molécules qui améliorent le transport d'agents pharmacologiquement actifs à travers la barrière hémato-encéphalique, des procédés d'amélioration du transport à travers la barrière hémato-encéphalique, et des procédés de traitement de troubles ou de maladies ayant une composante neurologique.
Latest bibliographic data on file with the International Bureau